Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience
Abstract Background and Aim Saroglitazar, a dual PPAR α/γ agonist, is useful in management of NAFLD and diabetic dyslipidemia. Here, we report the safety and efficacy of saroglitazar in NAFLD patients with or without diabetes including compensated cirrhosis. Methods Patients, started on saroglitazar...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Wiley
2023-03-01
|
| Collection: | JGH Open |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1002/jgh3.12878 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|